Knoll Capital Management, LLC Diversified Active

Location: Miami, FL

CIK: 0001325083 · Show all filings

Period: Q3 2013 (← Previous) (Next →)

Filing Date: Nov 15, 2013

Total Value: $187M (100.0% shares, 0.0% debt)

Holdings (11)

— Medivation, Inc. 79.5%

Value $149M Shares 2,484,101 Est. Cost $49.20 Unrealized —

— Ampio Pharmaceuticals Inc. 8.1%

Value $15.2M Shares 2,026,998 Est. Cost $6.38 Unrealized —

— Alcobra Ltd 5.7%

Value $10.59M Shares 587,000 Est. Cost $6.85 Unrealized —

— Vivus Inc. 2.5%

Value $4.65M Shares 500,000 Est. Cost $9.30 Unrealized —

GNW Genworth Finl Inc 1.4%

Value $2.701M Shares 211,000 Est. Cost $10.41 Unrealized +20.4%

— Sequenom Inc. 1.3%

Value $2.386M Shares 893,600 Est. Cost $4.21 Unrealized —

— Newlink Genetics Corp 0.8%

Value $1.454M Shares 77,437 Est. Cost $19.35 Unrealized —

— Keryx Biopharmaceuticals Inc. 0.5%

Value $1.009M Shares 100,000 Est. Cost $7.47 Unrealized —

— Celgene Corp 0.1%

Value $225K Shares 27,925 Est. Cost $7.31 Unrealized —

EXAS Exact Sciences Corp 0.1%

Value $165K Shares 14,000 Est. Cost $12.83 Unrealized 0.0%

— Echo Therapeutics Inc. 0.1%

Value $123K Shares 44,445 Est. Cost $0.25 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Medivation, Inc.	2,484,101	$149M	79.5%	$49.20	—	Com	58501N101
—	Ampio Pharmaceuticals Inc.	2,026,998	$15.2M	8.1%	$6.38	—	Com	03209T109
—	Alcobra Ltd	587,000	$10.59M	5.7%	$6.85	—	SHS	M2239P109
—	Vivus Inc.	500,000	$4.65M	2.5%	$9.30	—	Com	928551100
GNW	Genworth Finl Inc	211,000	$2.701M	1.4%	$10.41	+20.4%	Com CL A	37247D106
—	Sequenom Inc.	893,600	$2.386M	1.3%	$4.21	—	Com New	817337405
—	Newlink Genetics Corp	77,437	$1.454M	0.8%	$19.35	—	Com	651511107
—	Keryx Biopharmaceuticals Inc.	100,000	$1.009M	0.5%	$7.47	—	Com	492515101
—	Celgene Corp	27,925	$225K	0.1%	$7.31	—	Com	151020104
EXAS	Exact Sciences Corp	14,000	$165K	0.1%	$12.83	0.0%	Com	30063P105
—	Echo Therapeutics Inc.	44,445	$123K	0.1%	$0.25	—	Com New	27876L206